Abstract
Eukaryotic cells respond to various types of stresses caused by changes in the extracellular environment. Intracellular factors, such as the accumulation of misfolded proteins in the endoplasmic reticulum (ER), also cause stress and activate the unfolded protein response (UPR), which induces the expression of chaperones and proteins involved in the recovery process. However, if the stress is excessive or sustained, and ER function cannot be restored, the UPR triggers apoptosis, thereby removing the affected cell. It is now apparent that ER stress is also a potent trigger for autophagy, a self-degradative process that has an adaptive function. This review surveys the intersection of ER stress and autophagy and highlights the potential therapeutic implications thereof.
Keywords: Autophagy, chaperones, endoplasmic reticulum stress, apoptosis, unfolded protein responses.
Current Molecular Medicine
Title:ER Stress and Autophagy
Volume: 15 Issue: 8
Author(s): W. -S. Lee, W. -H. Yoo and H. -J. Chae
Affiliation:
Keywords: Autophagy, chaperones, endoplasmic reticulum stress, apoptosis, unfolded protein responses.
Abstract: Eukaryotic cells respond to various types of stresses caused by changes in the extracellular environment. Intracellular factors, such as the accumulation of misfolded proteins in the endoplasmic reticulum (ER), also cause stress and activate the unfolded protein response (UPR), which induces the expression of chaperones and proteins involved in the recovery process. However, if the stress is excessive or sustained, and ER function cannot be restored, the UPR triggers apoptosis, thereby removing the affected cell. It is now apparent that ER stress is also a potent trigger for autophagy, a self-degradative process that has an adaptive function. This review surveys the intersection of ER stress and autophagy and highlights the potential therapeutic implications thereof.
Export Options
About this article
Cite this article as:
Lee -S. W., Yoo -H. W. and Chae -J. H., ER Stress and Autophagy, Current Molecular Medicine 2015; 15 (8) . https://dx.doi.org/10.2174/1566524015666150921105453
DOI https://dx.doi.org/10.2174/1566524015666150921105453 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Chitosan Derivatives with Antimicrobial, Antitumour and Antioxidant Activities - a Review
Current Pharmaceutical Design The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma <i>via Akt</i> Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine HR-MAS NMR Spectroscopy: A Practical Guide for Natural Samples
Current Organic Chemistry Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Electrohydrodynamic Preparation of Nanomedicines
Current Topics in Medicinal Chemistry Transferrin Coupled Liposomes for Enhanced Brain Delivery of Doxorubicin
Vascular Disease Prevention (Discontinued) The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Anti-Infective Agents in Medicinal Chemistry Apoptosis in Drug Response
Current Pharmacogenomics Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
Current Cancer Drug Targets Arsenic Trioxide and Artemisinin Act Synergistically to Kill Tumor Cells In Vitro
Anti-Cancer Agents in Medicinal Chemistry State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent
Current Cancer Drug Targets Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry